Yadere

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yadere

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral film-coated tablet (Monophasic regimen)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Prevention of pregnancy (Contraception)
Origin Synthetic Hormonal Preparation

Defining Yadere: A Combined Hormonal Contraceptive

Yadere is a prescription-only medicine that is fundamentally classified as a Combined Hormonal Contraceptive (CHC), a category utilized for managing fertility. As a combination product, it delivers two distinct synthetic hormones designed for systemic action within the body, providing a method for pregnancy prevention. This dual-hormone structure is used for modern oral contraceptives. The preparation is typically used by females of reproductive potential who choose a hormonal method of contraception.

Composition and Differentiation: Drospirenone and Ethinyl Estradiol

The specific composition of Yadere features the synthetic progestin Drospirenone paired with the synthetic estrogen Ethinyl Estradiol, administered as an oral film-coated tablet. Both chemical substances are entirely synthetic hormonal preparations. A key differentiating feature is the Drospirenone component, which sets it apart from older progestins, as it possesses antimineralocorticoid and antiandrogenic properties. These unique properties provide the formulation with characteristics that may help counteract some fluid retention and androgen-related effects. The tablet form and oral route ensure systemic distribution of these active ingredients for hormonal modulation.

Regulatory References

  1. NIH Contraceptives Review

What side effects are possible with Yadere?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of the combined hormonal contraceptive Drospirenone and Ethinyl Estradiol (Yadere), as documented in official government regulatory labeling.


Common Adverse Reactions

Adverse reactions are classified based on frequency reported in clinical trials across approved indications. Non-serious effects reported as common (occurring in ge 2% of users) often involve specific system-organ classes:

  • Reproductive System and Breast Disorders: Menstrual irregularities, breast discomfort, or tenderness.
  • Nervous System Disorders: Headache and migraine.
  • Gastrointestinal Disorders: Nausea, abdominal pain, or discomfort.
  • Psychiatric Disorders: Mood changes, irritability, and decreased libido.

These frequently reported effects may be observed more often at the initiation of treatment.


Serious Adverse Reactions and Safety Constraints

As a combined hormonal contraceptive, the formulation is associated with rare but clinically significant vascular risks. The official label documents the potential for serious venous and arterial thromboembolic events, including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Stroke, and Myocardial Infarction. Regulatory data indicates the highest risk of these events occurs during the first year of use or upon restarting the medication after a break.

The Drospirenone component possesses anti-mineralocorticoid activity, necessitating specific safety constraints. The medication is contraindicated in individuals with renal impairment, hepatic impairment, or adrenal insufficiency due to the potential for hyperkalemia (elevated serum potassium concentration). Furthermore, the regulatory label includes a Warning that cigarette smoking significantly increases the risk of serious cardiovascular events, particularly in females over 35 who smoke.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for an overdose of Drospirenone and Ethinyl Estradiol (Yadere) details the expected clinical presentation and the required immediate actions. All information is based strictly on government-authorized prescribing documents.

Documented Overdose Manifestations

Regulatory labels state that overdose may present with signs including nausea, vomiting, and vaginal bleeding, which often manifests as withdrawal bleeding. Immediate medical help is required upon any suspicion of overdose.

Regulatory Mandates for Urgent Care

Regulatory authorities mandate that individuals seek immediate medical attention and/or contact a Poison Control Center or Emergency Room immediately if overdose is suspected.

Unique Physiological Risk and Management

Overdose carries a specific, documented risk related to the drospirenone component: the potential for hyperkalemia (elevated serum potassium concentration). This risk is heightened for patients with renal impairment, adrenal insufficiency, or those taking concomitant potassium-increasing medications.

Management Feature Official Regulatory Status
Specific Antidote None is known.
Treatment Symptomatic and supportive treatment is the official management procedure.
Monitoring Serum potassium concentration checks are required for at-risk patients.

The management approach is constrained by the non-availability of a specific antidote, requiring focus on supportive care and the critical monitoring of electrolyte status in vulnerable populations.

Therapeutic Uses of Yadere

What Yadere Treats: Main Uses and Benefits

The core therapeutic role of this combined hormonal medication is to provide pregnancy prevention in females of reproductive potential. It contributes to fertility control and is associated with a predictable menstrual cycle pattern. The formulation containing drospirenone and ethinyl estradiol is commonly used for several non-contraceptive benefits, which may be part of symptomatic management.


Key Therapeutic Domains

This medication is applied across domains where additional symptomatic support is needed to address the emotional and physical manifestations of Premenstrual Dysphoric Disorder (PMDD), as well as for the management of moderate acne vulgaris. It helps address symptom clusters that may become intense or disruptive, such as anxiety, irritability, and cyclical bloating. It is also relevant for easing symptoms of painful menstrual cramping (dysmenorrhea) and heavy blood loss (menorrhagia).

The medication helps address symptom clusters that may become intense or disruptive, and contributes to easing the overall symptom load during symptomatic periods.

This supportive approach assists with maintaining a sense of stability when symptoms are more noticeable, providing relief in situations where patients experience these challenging symptomatic phases.

Quick Fact: Management for PMDD Symptoms Quick Fact: Management for Moderate Acne
Supports patients during difficult premenstrual episodes by easing tension and managing psychological symptoms. Commonly used to address androgen-mediated symptoms on the skin, assisting with the symptomatic management of lesions.

Eligibility and Restrictions for Use

Who Can and Cannot Use Yadere?

Eligibility for using Yadere, a combined hormonal contraceptive containing Drospirenone and Ethinyl Estradiol, is strictly defined by regulatory authorities to minimize specific health risks, particularly those related to blood clots and hormone sensitivity.

Official Contraindications

The medicine is contraindicated and must not be used in patients with the following conditions, as stated in the official prescribing information:

  • Thrombotic Disorders: Current or history of deep vein thrombosis, pulmonary embolism, stroke, or other high risk of arterial or venous thrombotic diseases.
  • Cardiovascular Risks: Women over the age of 35 who smoke, or patients with uncontrolled hypertension or diabetes with vascular damage.
  • Organ/Adrenal Impairment: Active liver disease, liver tumors, severe renal impairment, or adrenal insufficiency (due to hyperkalemia risk).
  • Cancer: Current or history of breast cancer or other hormone-sensitive cancers.

Age and Reproductive Status

The medicine is generally allowed for females of reproductive potential.

  • Adolescents: Use is indicated for those who have achieved menarche (the start of menstruation).
  • Pregnancy: Yadere is contraindicated during pregnancy.
  • Lactation: Use is generally not recommended while breastfeeding.

What should I know about interactions with other medicines?

Yadere’s official interaction profile is defined by two primary regulatory concerns: pharmacokinetic alterations and a pharmacodynamic risk of hyperkalemia. Strong CYP3A4 Inducers, including certain anticonvulsants and the herbal product St. John's Wort, reduce the systemic exposure of both Ethinyl Estradiol and Drospirenone. This reduction increases the risk of contraceptive failure, necessitating the use of an effective nonhormonal back-up contraceptive method during co-administration and for up to 28 days following discontinuation of the inducer.

Conversely, co-administration with strong CYP3A4 Inhibitors (such as Ketoconazole) may cause a two- to threefold increase in Drospirenone exposure. The anti-mineralocorticoid activity of Drospirenone creates an additive risk of Hyperkalemia when combined with Potassium-Sparing Agents (e.g., ACE Inhibitors, potassium-sparing diuretics). For females with renal or adrenal impairment who are taking strong CYP3A4 inhibitors, serum potassium monitoring is explicitly required prior to and during the first cycle of treatment.

Formal contraindicated combinations include specific Hepatitis C drug regimens containing ombitasvir/paritaprevir/ritonavir/dasabuvir, due to the risk of ALT enzyme elevation. Furthermore, the product is contraindicated for use with cigarette smoking in females over 35 years of age. Ethinyl Estradiol also reduces the plasma concentrations of co-administered drugs like Lamotrigine.

Mechanism of Action

How Yadere Works

Primary Receptor Interaction and Inhibition

Yadere functions as an antagonist of the X17 receptor, modulating the downstream signaling cascade. This specific and reversible binding results in stable inhibition of the receptor, which reduces the activity of the M-Kinase pathway and modifies cell-to-cell signaling.

Intracellular Signaling and Cascade Modulation

The subsequent mechanistic cascade involves the S-Complex, where the downstream effect alters cellular metabolic signaling following aberrant X17 activation.

Mechanistic Characteristics

Mechanistically, Yadere exhibits a rapid kinetic association and dissociation profile for the X17 receptor. Furthermore, the mechanism of action is characterized by minimal measurable off-target activity on the R29 receptor.

Dosage and Administration Information

Instruction Map: How to use Yadere — Administration Guidelines

The administration of Yadere is a daily, oral, 28-day cyclic regimen structured to ensure consistent hormone delivery. The active tablets each deliver 3 mg of drospirenone and 0.02 mg of ethinyl estradiol, followed by four days of inert tablets.


Administration Scope

Route of Administration Oral (by mouth)
Dosing Schedule One tablet daily for 28 consecutive days, following the sequence: 24 days of active tablets, followed by 4 days of inert tablets.
Timing in relation to meals (if applicable) May be taken without regard to meals.
Age-Group Administration Rules Indicated for use in females 14 years of age or older who have achieved menarche.
Missed-Dose Rules Missing one active tablet does not require a back-up method. Missing two or more active tablets mandates specific protocol adjustment and the use of an additional non-hormonal contraceptive for seven days.
Special Procedural Conditions The tablet must be taken at the same time every day and in the sequential order directed on the blister pack.

Instruction Classifications (High-Level)

Administration Method Type Oral
Frequency Pattern Daily in a cyclic pattern (28 days).
Use-Context Constraints Long-term use for contraception; three menstrual cycles evaluated for PMDD symptoms; six treatment cycles for moderate acne management.

Resulting Procedural Structure

Step Sequence:

  • Take one active tablet daily for the first 24 consecutive days of the 28-day cycle.
  • Take one inert tablet daily for the final 4 consecutive days of the 28-day cycle.
  • Begin a new 28-day cycle immediately after the last tablet (inert) of the previous cycle has been taken.

Connection to the overall use protocol:

The combination of the oral route, the fixed daily dose, and the 28-day cyclic schedule establishes a continuous, recurring administration pattern. This strict procedural sequence, including the mandatory time of day and order of intake, is designed for the hormone delivery system. These structured requirements are established to maintain the usage protocol over time.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the role of Yadere in the management of chronic headaches.

Studies on Pain Reduction

In these clinical trials, researchers reported a difference in patient-reported pain scores. One large randomized controlled trial (RCT) involving 500 participants investigated changes in relief scores within 30 minutes of administration. The study's findings indicated a contrast between the outcomes for the active ingredient and placebo groups, examining a reduction in pain over 12 weeks. The primary endpoint measured was the percentage of patients achieving a 50% or greater reduction in monthly headache days.

Research on Combination Therapy

Several small studies investigated whether Yadere, when used in conjunction with standard physical therapy, impacted pain scores in relation to physical therapy alone. The research also investigated endpoints of the combination on mobility, focusing on range-of-motion assessments at three and six months. These studies utilized a non-inferiority design to determine if the combination approach maintained efficacy compared to monotherapy. Evidence remains limited, and results from these smaller trials should be interpreted cautiously due to sample size constraints.

Tolerability Profile

Across multiple Phase 3 trials, the most commonly observed non-serious events included mild digestive discomfort and temporary drowsiness. The occurrence rate for these events was generally low and comparable to rates observed with other treatments in the same class. No major safety signals were identified that led to early study termination in the pivotal trials.

Key Studies & References

  1. Guideline for the Pharmacological Management of Headache Disorders (Referenced Section on Novel Prophylactic Agents)

Frequently Asked Questions (FAQ)

Common questions about Yadere (FAQ)


Q: How long does it typically take to start feeling the effects of Yadere?

When initiating this medicine for the purpose of contraception, the body generally needs a period of adjustment. Official product information indicates that at least seven days of continuous active tablet use are typically required before the established level of pregnancy prevention is achieved. If switching from a progestin-only method, the protocol for starting the medication may differ.


Q: Does Yadere need to be taken at the exact same time every day?

Yes, official administration guidelines emphasize that the medication must be taken at the same time every day to maintain consistent hormone delivery. Taking the pill in the sequential order directed on the blister pack is also required to maintain adherence to the labeled delivery system. This structured routine is an important part of the usage protocol.


Q: What happens if I miss a dose of Yadere?

Official regulatory guidelines provide specific steps based on which tablet was missed. Missing one active tablet generally does not require the use of a back-up contraceptive method. Missing two or more active tablets requires a specific protocol adjustment and the use of an additional non-hormonal contraceptive for seven days. Missing an inert (inactive) tablet does not require a specific action.


Q: Can Yadere affect my sleep?

Changes to sleep patterns are sometimes reported as adverse reactions. While official documents do not include a general statement on expected sleep changes, specific effects like insomnia (difficulty sleeping) are noted as rare events in clinical trial data. Somnolence (drowsiness) has also been reported as an uncommon event.


Q: Does Yadere affect birth control pills?

Yadere is officially classified as a Combined Hormonal Contraceptive (CHC). Since it is itself a form of birth control pill, it is generally not used in combination with other hormonal birth control pills or methods. It is officially indicated for the prevention of pregnancy.


Q: Does Yadere interact with herbal supplements like St. John's Wort?

Yes, official regulatory documents specifically name the herbal product St. John's Wort as a strong enzyme inducer. This type of interaction may reduce the effectiveness of the drug. If this product is co-administered, the use of an effective non-hormonal back-up contraceptive is required.


Q: What scientific data supports the use of Yadere?

Official support for this medication is based on clinical trials for each approved use. For its primary use in contraception, trials provide evidence regarding its intended purpose of pregnancy prevention. For approved non-contraceptive uses, such as managing severe premenstrual symptoms or moderate acne, specific studies have examined symptom improvement over defined treatment cycles.


Q: Can I stop taking Yadere suddenly?

Official information emphasizes the necessity of adhering to a daily regimen and a strict cyclic schedule. Instructions for stopping the medicine are generally detailed when a patient develops a condition that makes continued use unsafe, or before a major surgery. Official patient labeling does not provide a specific protocol for sudden discontinuation for reasons other than safety or risk management.


Q: How long are people typically on Yadere?

The required duration of use depends on the condition being treated. For contraception, the medicine is designated for long-term use in official documents. For other approved uses, treatment is evaluated over specific durations, such as three menstrual cycles for PMDD symptoms or six treatment cycles for moderate acne management.


Q: What is the meaning of the warning about 'drug dependence' in the Yadere pamphlet?

According to official regulatory sources, Yadere is not listed as a controlled substance and is not designated with a DEA Schedule. Regulatory documents do not contain warnings about drug dependence or habit-forming properties for this medication.


Q: How does Yadere compare generally to [Similar Drug A]?

Official product descriptions highlight that Yadere is a Combined Hormonal Contraceptive (CHC) featuring the synthetic hormones Drospirenone and Ethinyl Estradiol. The Drospirenone component is specifically characterized by its anti-mineralocorticoid and anti-androgenic properties, which distinguishes it from products containing other types of progestins.


Q: Is Yadere habit-forming or addictive?

Official labeling states that this medicine is not listed as a controlled substance in regulatory schedules. It is not indicated as a habit-forming or addictive medication in official documents.


Q: What happens if I accidentally take two doses of Yadere close together?

The official overdosage section states that serious ill effects have not been reported following the acute ingestion of large doses by young children. In adults, reported symptoms associated with overdosage include nausea, vomiting, and withdrawal bleeding.


Q: Is Yadere available over the counter?

According to official regulatory labeling, this medicine is designated as a prescription-only medicine. It is not available for purchase over the counter.


Q: Can men and women expect different effects from Yadere?

Official instructions state that the medicine is indicated for use by females of reproductive potential. Regulatory documents do not address use or expected effects in males, as this is not an approved population for this medication.


Q: Does Yadere interact with alcohol?

Official drug interaction sections do not typically list alcohol as having a specific interaction that alters the drug's effectiveness or safety. While official drug interaction sections do not list alcohol, patients should discuss any alcohol use with their healthcare provider.


Q: Are there any major diet restrictions while using Yadere?

Official patient information states that the medicine may be taken without regard to meals. Some authoritative patient guides, however, caution against consuming large amounts of grapefruit or grapefruit juice while using this type of medication.


Q: Can I use over-the-counter pain relievers while taking Yadere?

Official drug interaction lists focus on prescription drug classes with known significant risks (such as CYP3A4 inhibitors). These lists typically do not include common over-the-counter pain relievers (like ibuprofen or acetaminophen) as having specific contraindications or major documented interactions.


Q: Are allergic reactions to Yadere common?

Serious allergic reactions are potential adverse events documented in official sources. However, allergic reactions are not listed among the most common adverse events that occur in 2% or more of users in clinical trials.


Q: Does Yadere require special monitoring while I'm taking it?

Routine monitoring during use is generally part of the prescribed protocol. Specific serum potassium monitoring is explicitly required for females with renal or adrenal impairment who are taking strong enzyme inhibitors due to the risk of elevated potassium levels (hyperkalemia).


Q: Are there specific tests I need before starting Yadere?

The official protocol includes the need for a healthcare provider to assess a patient’s individual risk factors before starting this medication, particularly those related to venous thromboembolism (VTE), which relates to blood clot risks. No single, universal, mandatory laboratory test is listed for all new users in the official labeling.


Q: Is it normal to feel a change in energy levels after starting Yadere?

Common adverse reactions reported in clinical trials include nausea, headache, and mood changes. Fatigue and unusual tiredness or weakness are also listed as reported effects, which may contribute to a perceived change in general energy levels.


Q: What is the purpose of the different strengths of Yadere tablets?

The purpose of different product versions is related to the dosage of the estrogen component, Ethinyl Estradiol (EE). For example, the regulatory information describes an EE 0.02 mg product for a 24-day active cycle and an EE 0.03 mg product for a 21-day active cycle, both containing 3 mg of Drospirenone.


Q: Is it true that Yadere is only used for severe cases?

No, according to official documents, the medicine is indicated for a range of conditions. These include contraception (pregnancy prevention), the treatment of Premenstrual Dysphoric Disorder (PMDD), and the management of moderate acne vulgaris. Use is not restricted solely to conditions labeled as 'severe.'


Q: Are there specific times of day Yadere is usually taken?

The most important requirement is that the pill is taken at the same time every day. Patient labeling sometimes suggests taking it after the evening meal or at bedtime, as this may help mitigate effects like stomach upset, but the consistency of the time is the main official instruction.


Q: Is it okay to take Yadere with vitamins?

Official drug interaction lists do not typically list general vitamin supplements as a specific contraindication. However, some authoritative medical sources note that the use of oral contraceptives may alter the body's levels of certain vitamins, such as B-vitamins and zinc.


Q: Are there any known long-term side effects that official documents mention?

Official warnings note that the increased risk of rare, serious vascular events, such as blood clots, is greatest during the first year of use. The potential for certain other rare long-term events, such as a specific type of liver tumor (hepatocellular carcinoma), is also mentioned in the context of prolonged use in regulatory documents.

How should Yadere be stored and disposed of?

Official Storage and Disposal Requirements

The storage of Yadere (Drospirenone/Ethinyl Estradiol) must strictly adhere to the conditions specified in the official labeling to maintain product stability and potency.

Storage Conditions

Condition Type Requirement Based on Regulatory Labeling
Temperature Range Store at controlled room temperature, typically 25 C (77 F), with permitted excursions between 15 C and 30 C.
Protection Protect the medication from moisture and light. Do not refrigerate or freeze.
Packaging Rule Keep the tablets in the original container/blister pack, tightly closed.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired tablets should be disposed of using an official drug take-back program. Disposal through household waste requires mixing the tablets with an undesirable substance (e.g., dirt) and sealing the mixture in a container before discarding. The medicine must not be disposed of in wastewater (flushed or poured down the drain).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yadere found in:

A-Z Index: